Peptide Bioavailability: How Subcutaneous, Oral, and Nasal Delivery Routes Compare

Peptide therapeutics present a persistent pharmacokinetic challenge: most peptides are rapidly degraded by proteolytic enzymes, poorly absorbed across biological membranes, and subject to significant first-pass metabolism. The route of administration directly shapes how much of a given peptide reaches systemic circulation and in what timeframe. Understanding bioavailability differences across delivery methods is foundational for interpreting peptide research, and the Peptide Register catalogues these distinctions across its peptide profiles database to support researchers and clinicians in evaluating the evidence.

This post examines what published studies report about three primary delivery routes: subcutaneous injection, oral administration, and intranasal delivery.

What Bioavailability Means for Peptide Research

Bioavailability refers to the fraction of an administered substance that reaches systemic circulation in an unchanged, active form. For small-molecule drugs, oral bioavailability above 50% is common. Peptides, however, face unique obstacles. Their molecular weight, hydrophilicity, and susceptibility to enzymatic degradation in the gastrointestinal tract and liver mean that most unmodified peptides have oral bioavailability below 2%. This is a well-documented constraint in pharmaceutical science and a primary reason most approved peptide therapies rely on parenteral administration.

For researchers evaluating peptide study data, the delivery method used in a given trial is not incidental. A result observed with subcutaneous injection cannot be assumed to replicate with oral dosing unless bioequivalence has been independently demonstrated. The Peptide Register glossary provides definitions for key pharmacokinetic terms referenced throughout this discussion.

Subcutaneous Injection: The Current Standard

Subcutaneous injection remains the most widely used delivery route for peptide therapeutics in both clinical practice and research settings. Subcutaneous injection of peptides typically achieves bioavailability between 60% and 100%, depending on the specific molecule and formulation. This route bypasses gastrointestinal degradation and hepatic first-pass metabolism, allowing relatively predictable absorption from the subcutaneous tissue depot into systemic circulation.

Published pharmacokinetic data for insulin, a well-characterized peptide, consistently demonstrates subcutaneous bioavailability in the range of 55% to 70%. GLP-1 receptor agonists such as semaglutide achieve near-complete bioavailability via subcutaneous administration. Most peptide clinical trials to date have used subcutaneous injection as the primary delivery method, which means the majority of published efficacy and safety data reflects this route.

The practical limitations are well known: injection-site reactions, the need for cold-chain storage in many cases, and patient compliance challenges. These constraints have driven significant research interest in non-injectable alternatives.

Oral Peptide Delivery: Progress and Persistent Challenges

Oral bioavailability of unmodified peptides is generally below 2% due to enzymatic degradation and poor membrane permeability. The development of oral semaglutide (Rybelsus) represented a notable advance. Oral semaglutide uses a permeation enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), to facilitate absorption in the stomach. Even with this technology, oral semaglutide has a reported bioavailability of approximately 0.4% to 1%, requiring substantially higher doses to achieve comparable plasma concentrations to the subcutaneous formulation.

Research into oral delivery strategies extends beyond permeation enhancers. Enteric coatings, nanoparticle encapsulation, and protease inhibitor co-formulations have all been investigated in preclinical models. Many of these approaches show promise in animal studies but have not yet been validated in large-scale human trials. Researchers should note that animal gastrointestinal physiology differs substantially from human physiology, and oral bioavailability results from rodent models frequently do not translate directly to human outcomes.

Intranasal Delivery: A Middle Ground Under Investigation

Intranasal peptide delivery offers a non-invasive route that avoids gastrointestinal degradation. Intranasal delivery of peptides generally achieves bioavailability between 1% and 30%, varying substantially by peptide size and formulation. Smaller peptides tend to cross the nasal mucosa more readily. Desmopressin, a synthetic vasopressin analogue, has been administered intranasally for decades with reported bioavailability of approximately 3% to 5%.

Intranasal oxytocin has been widely studied in behavioral research, though questions about how much peptide actually reaches central targets versus peripheral circulation remain active areas of investigation. A 2018 systematic review noted significant variability in intranasal oxytocin pharmacokinetic data across studies, highlighting the need for standardized protocols and more rigorous bioavailability assessments.

Nasal absorption enhancers, mucoadhesive formulations, and nanoparticle carriers are under investigation to improve intranasal peptide bioavailability. Much of this work remains preclinical. The regulatory pathway for intranasal peptide products also involves additional considerations around local mucosal tolerability and long-term nasal tissue effects.

Implications for Interpreting Peptide Research

The delivery route used in any peptide study fundamentally shapes the results. Bioavailability differences mean that efficacy findings from subcutaneous injection studies cannot be extrapolated to oral or nasal formulations without dedicated pharmacokinetic bridging studies. Researchers reviewing peptide literature should always note the administration route, formulation details, and whether bioavailability was directly measured or assumed.

The Peptide Register documents delivery methods and bioavailability data within its structured peptide profiles to help researchers contextualize published findings. As peptide delivery science evolves, distinguishing between validated human pharmacokinetic data and preclinical projections remains essential for rigorous evidence appraisal.

No delivery method is inherently superior; each involves trade-offs between bioavailability, patient burden, stability requirements, and regulatory complexity. What matters for the research community is transparency about these trade-offs and careful interpretation of data generated under specific delivery conditions.